Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-05-17

AUTHORS

Kim Margolin, Timothy W. Synold, Primo Lara, Paul Frankel, Simon F. Lacey, David I. Quinn, Tracey Baratta, Janice P. Dutcher, Bixin Xi, Don J. Diamond, David R. Gandara

ABSTRACT

PurposeOblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. This study was designed to evaluate the combination of oblimersen with α-Interferon in advanced renal cancer. Trial endpoints were antitumor efficacy and toxicity, pharmacokinetics, and evidence of apoptosis in peripheral blood mononuclear cells.MethodsPatients with measurable advanced renal cancer and 0–1 prior therapy were eligible. Treatment consisted of oblimersen, 7 mg/kg/day, as a continuous intravenous infusion 7 days of every 14 day cycle, plus α-IFN, 5 million units/m2 subcutaneously, days 4 and 6 of the first oblimersen infusion, then thrice weekly. Blood for laboratory correlates was collected before treatment, during oblimersen, and during therapy with both agents.ResultsTwenty-three patients were enrolled, five of whom had prior systemic therapy (three with prior high-dose interleukin-2). The median number of treatment cycles was 4 (range 1–12). One patient had a partial response lasting 2.5 months. The Grade 3–4 toxicities were fatigue, fever, myelosuppression, hepatic enzyme and metabolic abnormalities. Laboratory analyses of CD3+ lymphocyte apoptotic markers demonstrated no change between pre-treatment and on-treatment levels of bcl-2 or Annexin/PI positivity by flow cytometry. Mean oblimersen steady-state plasma concentration and clearance was 2.3 ± 0.9 μg/ml and 0.15 ± 0.07 l/h/kg, respectively.ConclusionsOblimersen given in this dose and schedule with α-IFN does not appear sufficiently active to warrant further study in advanced renal cancer. Combinations with newer targeted agents may show greater promise. More... »

PAGES

705-711

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-007-0200-6

DOI

http://dx.doi.org/10.1007/s00432-007-0200-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019128922

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17508219


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunologic Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thionucleotides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Margolin", 
        "givenName": "Kim", 
        "id": "sg:person.0646721507.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646721507.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Synold", 
        "givenName": "Timothy W.", 
        "id": "sg:person.010054353347.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010054353347.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, Davis, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "University of California, Davis, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lara", 
        "givenName": "Primo", 
        "id": "sg:person.01052071350.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052071350.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Information Sciences, City of Hope, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Information Sciences, City of Hope, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Frankel", 
        "givenName": "Paul", 
        "id": "sg:person.0752727232.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752727232.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory of Vaccine Research, City of Hope, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Laboratory of Vaccine Research, City of Hope, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lacey", 
        "givenName": "Simon F.", 
        "id": "sg:person.01364713364.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364713364.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Information Sciences, City of Hope, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Information Sciences, City of Hope, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baratta", 
        "givenName": "Tracey", 
        "id": "sg:person.0754366773.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754366773.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Our Lady of Mercy Medical Center, Bronx, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417317.7", 
          "name": [
            "Our Lady of Mercy Medical Center, Bronx, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dutcher", 
        "givenName": "Janice P.", 
        "id": "sg:person.0760406720.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xi", 
        "givenName": "Bixin", 
        "id": "sg:person.01160474102.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160474102.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory of Vaccine Research, City of Hope, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Laboratory of Vaccine Research, City of Hope, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Diamond", 
        "givenName": "Don J.", 
        "id": "sg:person.01206212664.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206212664.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, Davis, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "University of California, Davis, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gandara", 
        "givenName": "David R.", 
        "id": "sg:person.0644235622.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644235622.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1994.22", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029242322", 
          "https://doi.org/10.1038/bjc.1994.22"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/349254a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037208457", 
          "https://doi.org/10.1038/349254a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-05-17", 
    "datePublishedReg": "2007-05-17", 
    "description": "PurposeOblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. This study was designed to evaluate the combination of oblimersen with \u03b1-Interferon in advanced renal cancer. Trial endpoints were antitumor efficacy and toxicity, pharmacokinetics, and evidence of apoptosis in peripheral blood mononuclear cells.MethodsPatients with measurable advanced renal cancer and 0\u20131 prior therapy were eligible. Treatment consisted of oblimersen, 7\u00a0mg/kg/day, as a continuous intravenous infusion 7\u00a0days of every 14\u00a0day cycle, plus \u03b1-IFN, 5\u00a0million units/m2 subcutaneously, days\u00a04 and 6 of the first oblimersen infusion, then thrice weekly. Blood for laboratory correlates was collected before treatment, during oblimersen, and during therapy with both agents.ResultsTwenty-three patients were enrolled, five of whom had prior systemic therapy (three with prior high-dose interleukin-2). The median number of treatment cycles was 4 (range 1\u201312). One patient had a partial response lasting 2.5\u00a0months. The Grade 3\u20134 toxicities were fatigue, fever, myelosuppression, hepatic enzyme and metabolic abnormalities. Laboratory analyses of CD3+ lymphocyte apoptotic markers demonstrated no change between pre-treatment and on-treatment levels of bcl-2 or Annexin/PI positivity by flow cytometry. Mean oblimersen steady-state plasma concentration and clearance was 2.3\u00a0\u00b1\u00a00.9\u00a0\u03bcg/ml and 0.15\u00a0\u00b1\u00a00.07 l/h/kg, respectively.ConclusionsOblimersen given in this dose and schedule with \u03b1-IFN does not appear sufficiently active to warrant further study in advanced renal cancer. Combinations with newer targeted agents may show greater promise.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-007-0200-6", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "133"
      }
    ], 
    "keywords": [
      "advanced renal cancer", 
      "renal cancer", 
      "\u03b1-interferon", 
      "\u03b1-IFN", 
      "peripheral blood mononuclear cells", 
      "steady-state plasma concentrations", 
      "combination of oblimersen", 
      "California Cancer Consortium", 
      "ResultsTwenty-three patients", 
      "metastatic renal cancer", 
      "phase II study", 
      "blood mononuclear cells", 
      "Bcl-2", 
      "units/m2", 
      "evidence of apoptosis", 
      "prior therapy", 
      "systemic therapy", 
      "partial response", 
      "II study", 
      "metabolic abnormalities", 
      "trial endpoints", 
      "mononuclear cells", 
      "laboratory correlates", 
      "plasma concentrations", 
      "median number", 
      "grade 3", 
      "hepatic enzymes", 
      "anti-apoptotic proteins", 
      "treatment cycles", 
      "Cancer Consortium", 
      "cancer", 
      "antitumor efficacy", 
      "flow cytometry", 
      "oblimersen", 
      "apoptotic markers", 
      "therapy", 
      "Further studies", 
      "patients", 
      "day cycle", 
      "days", 
      "treatment", 
      "toxicity", 
      "MethodsPatients", 
      "myelosuppression", 
      "fever", 
      "CD3", 
      "infusion", 
      "pharmacokinetics", 
      "treatment levels", 
      "agents", 
      "abnormalities", 
      "blood", 
      "dose", 
      "endpoint", 
      "months", 
      "laboratory analysis", 
      "positivity", 
      "clearance", 
      "cytometry", 
      "study", 
      "efficacy", 
      "apoptosis", 
      "markers", 
      "thrice", 
      "correlates", 
      "cells", 
      "fatigue", 
      "oligodeoxynucleotides", 
      "antisense", 
      "response", 
      "combination", 
      "evidence", 
      "levels", 
      "schedule", 
      "protein", 
      "great promise", 
      "genes", 
      "m2", 
      "enzyme", 
      "changes", 
      "concentration", 
      "promise", 
      "cycle", 
      "number", 
      "consortium", 
      "analysis"
    ], 
    "name": "Oblimersen and \u03b1-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium", 
    "pagination": "705-711", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019128922"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-007-0200-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17508219"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-007-0200-6", 
      "https://app.dimensions.ai/details/publication/pub.1019128922"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_439.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-007-0200-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-007-0200-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-007-0200-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-007-0200-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-007-0200-6'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      21 PREDICATES      125 URIs      115 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-007-0200-6 schema:about N0b2b64f90873497dbd9d471405be86a1
2 N0ba9a7c47e614ec39d5e0136ef740f41
3 N22255690c87c4c79913f9d2fb1b83e92
4 N3e8774ebeb174224a9e903237452634f
5 N43f790316e85459ab37a96d4706e6389
6 N7f4e73c6fe714f908f47b2bd87ba7327
7 N8d2132bdbc284cc49fe50ef7065e575e
8 N911935aba3ca4dd9843c8360f7603481
9 N971411d2eb024ecd9a676ae9d1394204
10 Nbc6f167d12e54d5eb23ce6a898fb744c
11 Nd1e818c4e1ea434784d82fcba23d148a
12 Nd9114530816e4c81ab38c75d8a92b6fa
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author Nf7e1e372eded4affb9b4f77d859f5995
16 schema:citation sg:pub.10.1038/349254a0
17 sg:pub.10.1038/bjc.1994.22
18 schema:datePublished 2007-05-17
19 schema:datePublishedReg 2007-05-17
20 schema:description PurposeOblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. This study was designed to evaluate the combination of oblimersen with α-Interferon in advanced renal cancer. Trial endpoints were antitumor efficacy and toxicity, pharmacokinetics, and evidence of apoptosis in peripheral blood mononuclear cells.MethodsPatients with measurable advanced renal cancer and 0–1 prior therapy were eligible. Treatment consisted of oblimersen, 7 mg/kg/day, as a continuous intravenous infusion 7 days of every 14 day cycle, plus α-IFN, 5 million units/m2 subcutaneously, days 4 and 6 of the first oblimersen infusion, then thrice weekly. Blood for laboratory correlates was collected before treatment, during oblimersen, and during therapy with both agents.ResultsTwenty-three patients were enrolled, five of whom had prior systemic therapy (three with prior high-dose interleukin-2). The median number of treatment cycles was 4 (range 1–12). One patient had a partial response lasting 2.5 months. The Grade 3–4 toxicities were fatigue, fever, myelosuppression, hepatic enzyme and metabolic abnormalities. Laboratory analyses of CD3+ lymphocyte apoptotic markers demonstrated no change between pre-treatment and on-treatment levels of bcl-2 or Annexin/PI positivity by flow cytometry. Mean oblimersen steady-state plasma concentration and clearance was 2.3 ± 0.9 μg/ml and 0.15 ± 0.07 l/h/kg, respectively.ConclusionsOblimersen given in this dose and schedule with α-IFN does not appear sufficiently active to warrant further study in advanced renal cancer. Combinations with newer targeted agents may show greater promise.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N8550a5245c084a5f847997134342818a
24 Nb635eb4290b540b4be2c92d27be3f40e
25 sg:journal.1313647
26 schema:keywords Bcl-2
27 CD3
28 California Cancer Consortium
29 Cancer Consortium
30 Further studies
31 II study
32 MethodsPatients
33 ResultsTwenty-three patients
34 abnormalities
35 advanced renal cancer
36 agents
37 analysis
38 anti-apoptotic proteins
39 antisense
40 antitumor efficacy
41 apoptosis
42 apoptotic markers
43 blood
44 blood mononuclear cells
45 cancer
46 cells
47 changes
48 clearance
49 combination
50 combination of oblimersen
51 concentration
52 consortium
53 correlates
54 cycle
55 cytometry
56 day cycle
57 days
58 dose
59 efficacy
60 endpoint
61 enzyme
62 evidence
63 evidence of apoptosis
64 fatigue
65 fever
66 flow cytometry
67 genes
68 grade 3
69 great promise
70 hepatic enzymes
71 infusion
72 laboratory analysis
73 laboratory correlates
74 levels
75 m2
76 markers
77 median number
78 metabolic abnormalities
79 metastatic renal cancer
80 mononuclear cells
81 months
82 myelosuppression
83 number
84 oblimersen
85 oligodeoxynucleotides
86 partial response
87 patients
88 peripheral blood mononuclear cells
89 pharmacokinetics
90 phase II study
91 plasma concentrations
92 positivity
93 prior therapy
94 promise
95 protein
96 renal cancer
97 response
98 schedule
99 steady-state plasma concentrations
100 study
101 systemic therapy
102 therapy
103 thrice
104 toxicity
105 treatment
106 treatment cycles
107 treatment levels
108 trial endpoints
109 units/m2
110 α-IFN
111 α-interferon
112 schema:name Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium
113 schema:pagination 705-711
114 schema:productId N0cf7e870df314e2882da31f991bf5678
115 N6b64449eb2ae45aeb93aed464bda56e8
116 Nadd79a8d1ee44de08d6d04cfffa88656
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019128922
118 https://doi.org/10.1007/s00432-007-0200-6
119 schema:sdDatePublished 2022-09-02T15:51
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N8ad89f642ecd46a2b04895933afa9c2c
122 schema:url https://doi.org/10.1007/s00432-007-0200-6
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N0b2b64f90873497dbd9d471405be86a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Thionucleotides
128 rdf:type schema:DefinedTerm
129 N0ba9a7c47e614ec39d5e0136ef740f41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 N0cf7e870df314e2882da31f991bf5678 schema:name pubmed_id
133 schema:value 17508219
134 rdf:type schema:PropertyValue
135 N22255690c87c4c79913f9d2fb1b83e92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Interferon-alpha
137 rdf:type schema:DefinedTerm
138 N3e8774ebeb174224a9e903237452634f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Immunologic Factors
140 rdf:type schema:DefinedTerm
141 N42266f85d8a5493abf696cef97622605 rdf:first sg:person.01013134010.15
142 rdf:rest Na71e5bfe56024b0fa0a74cec83dda7e3
143 N43454e70fac541fc8ecb50b692522d75 rdf:first sg:person.0644235622.37
144 rdf:rest rdf:nil
145 N43f790316e85459ab37a96d4706e6389 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 N4ae39ce5ef624e0f9f53d60bb2720f18 rdf:first sg:person.0760406720.36
149 rdf:rest Nbe2caf02bf1f4f1bbfe1820ecd1c6e84
150 N6b64449eb2ae45aeb93aed464bda56e8 schema:name dimensions_id
151 schema:value pub.1019128922
152 rdf:type schema:PropertyValue
153 N7f4e73c6fe714f908f47b2bd87ba7327 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Middle Aged
155 rdf:type schema:DefinedTerm
156 N8164919c89fa45b2a8adf15b486e7e18 rdf:first sg:person.010054353347.22
157 rdf:rest Nd4f8c264c3ee49558ca9cdd386d1119d
158 N8550a5245c084a5f847997134342818a schema:volumeNumber 133
159 rdf:type schema:PublicationVolume
160 N8ad89f642ecd46a2b04895933afa9c2c schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 N8d2132bdbc284cc49fe50ef7065e575e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Apoptosis
164 rdf:type schema:DefinedTerm
165 N911935aba3ca4dd9843c8360f7603481 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Adult
167 rdf:type schema:DefinedTerm
168 N971411d2eb024ecd9a676ae9d1394204 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Kidney Neoplasms
170 rdf:type schema:DefinedTerm
171 N9a01a044b1ce4b8db455e88580d99e68 rdf:first sg:person.01206212664.64
172 rdf:rest N43454e70fac541fc8ecb50b692522d75
173 Na71e5bfe56024b0fa0a74cec83dda7e3 rdf:first sg:person.0754366773.21
174 rdf:rest N4ae39ce5ef624e0f9f53d60bb2720f18
175 Nadd79a8d1ee44de08d6d04cfffa88656 schema:name doi
176 schema:value 10.1007/s00432-007-0200-6
177 rdf:type schema:PropertyValue
178 Nb635eb4290b540b4be2c92d27be3f40e schema:issueNumber 10
179 rdf:type schema:PublicationIssue
180 Nb82edfb5e9d349db928d592b59ff4739 rdf:first sg:person.0752727232.51
181 rdf:rest Nd3e3e6c4dd8c4766b922910047b0fab0
182 Nbc6f167d12e54d5eb23ce6a898fb744c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Male
184 rdf:type schema:DefinedTerm
185 Nbe2caf02bf1f4f1bbfe1820ecd1c6e84 rdf:first sg:person.01160474102.34
186 rdf:rest N9a01a044b1ce4b8db455e88580d99e68
187 Nd1e818c4e1ea434784d82fcba23d148a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Humans
189 rdf:type schema:DefinedTerm
190 Nd3e3e6c4dd8c4766b922910047b0fab0 rdf:first sg:person.01364713364.00
191 rdf:rest N42266f85d8a5493abf696cef97622605
192 Nd4f8c264c3ee49558ca9cdd386d1119d rdf:first sg:person.01052071350.35
193 rdf:rest Nb82edfb5e9d349db928d592b59ff4739
194 Nd9114530816e4c81ab38c75d8a92b6fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Antineoplastic Combined Chemotherapy Protocols
196 rdf:type schema:DefinedTerm
197 Nf7e1e372eded4affb9b4f77d859f5995 rdf:first sg:person.0646721507.30
198 rdf:rest N8164919c89fa45b2a8adf15b486e7e18
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
203 schema:name Oncology and Carcinogenesis
204 rdf:type schema:DefinedTerm
205 sg:journal.1313647 schema:issn 0171-5216
206 1432-1335
207 schema:name Journal of Cancer Research and Clinical Oncology
208 schema:publisher Springer Nature
209 rdf:type schema:Periodical
210 sg:person.010054353347.22 schema:affiliation grid-institutes:grid.410425.6
211 schema:familyName Synold
212 schema:givenName Timothy W.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010054353347.22
214 rdf:type schema:Person
215 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
216 schema:familyName Quinn
217 schema:givenName David I.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
219 rdf:type schema:Person
220 sg:person.01052071350.35 schema:affiliation grid-institutes:grid.27860.3b
221 schema:familyName Lara
222 schema:givenName Primo
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052071350.35
224 rdf:type schema:Person
225 sg:person.01160474102.34 schema:affiliation grid-institutes:grid.410425.6
226 schema:familyName Xi
227 schema:givenName Bixin
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160474102.34
229 rdf:type schema:Person
230 sg:person.01206212664.64 schema:affiliation grid-institutes:grid.410425.6
231 schema:familyName Diamond
232 schema:givenName Don J.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206212664.64
234 rdf:type schema:Person
235 sg:person.01364713364.00 schema:affiliation grid-institutes:grid.410425.6
236 schema:familyName Lacey
237 schema:givenName Simon F.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364713364.00
239 rdf:type schema:Person
240 sg:person.0644235622.37 schema:affiliation grid-institutes:grid.27860.3b
241 schema:familyName Gandara
242 schema:givenName David R.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644235622.37
244 rdf:type schema:Person
245 sg:person.0646721507.30 schema:affiliation grid-institutes:grid.410425.6
246 schema:familyName Margolin
247 schema:givenName Kim
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646721507.30
249 rdf:type schema:Person
250 sg:person.0752727232.51 schema:affiliation grid-institutes:grid.410425.6
251 schema:familyName Frankel
252 schema:givenName Paul
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752727232.51
254 rdf:type schema:Person
255 sg:person.0754366773.21 schema:affiliation grid-institutes:grid.410425.6
256 schema:familyName Baratta
257 schema:givenName Tracey
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754366773.21
259 rdf:type schema:Person
260 sg:person.0760406720.36 schema:affiliation grid-institutes:grid.417317.7
261 schema:familyName Dutcher
262 schema:givenName Janice P.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36
264 rdf:type schema:Person
265 sg:pub.10.1038/349254a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037208457
266 https://doi.org/10.1038/349254a0
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/bjc.1994.22 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029242322
269 https://doi.org/10.1038/bjc.1994.22
270 rdf:type schema:CreativeWork
271 grid-institutes:grid.27860.3b schema:alternateName University of California, Davis, CA, USA
272 schema:name University of California, Davis, CA, USA
273 rdf:type schema:Organization
274 grid-institutes:grid.410425.6 schema:alternateName Division of Information Sciences, City of Hope, Duarte, CA, USA
275 Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA
276 Laboratory of Vaccine Research, City of Hope, Duarte, CA, USA
277 schema:name Division of Information Sciences, City of Hope, Duarte, CA, USA
278 Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, 91010-3000, Duarte, CA, USA
279 Laboratory of Vaccine Research, City of Hope, Duarte, CA, USA
280 rdf:type schema:Organization
281 grid-institutes:grid.417317.7 schema:alternateName Our Lady of Mercy Medical Center, Bronx, NY, USA
282 schema:name Our Lady of Mercy Medical Center, Bronx, NY, USA
283 rdf:type schema:Organization
284 grid-institutes:grid.42505.36 schema:alternateName USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
285 schema:name USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...